Introduction to Future Directions For Antiangiogenic Therapy In Lung Cancer
Welcome to our comprehensive guide on Future Directions For Antiangiogenic Therapy In Lung Cancer. Enriqueta Felip, MD, PhD; Joachim G. Aerts, MD, PhD; and Roy S. Herbst, MD, PhD, outline some of the
Future Directions For Antiangiogenic Therapy In Lung Cancer Comprehensive Overview
H. Jack West, MD, predicts how the therapeutic landscape in non–small cell Marina Garassino, MD; Enriqueta Felip, MD, PhD; Joachim G. Aerts, MD, PhD; and Roy S. Herbst, MD, PhD, describe the ... Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, comments ...
Panelists Mark A. Socinski, MD; Mark G. Kris, MD; David R. Spigel, MD; Ross Camidge, MD, PhD; and Jared Weiss, MD, discuss ...
Summary & Highlights for Future Directions For Antiangiogenic Therapy In Lung Cancer
- Marina Garassino, MD; Roy S. Herbst, MD, PhD; Enriqueta Felip, MD, PhD; and Joachim G. Aerts, MD, PhD, discuss the ...
- Amy Moore, PhD, LUNGevity Foundation, San Carlos, CA, discusses
- Corey J. Langer, MD, FACP, remarks on the significance of
- Expert panelists review considerations for combining bevacizumab with chemoimmunotherapy in appropriate patients with ...
- Joshua Sabari, MD, New York University Langone Health, New York, NY, comments on the potential of combination strategies in ...
In summary, understanding Future Directions For Antiangiogenic Therapy In Lung Cancer gives us a better perspective.
